Pharmaceutical nanotechnology experts are specialized scientists and researchers who focus on applying nanotechnology principles to the field of drug development and delivery. These experts leverage the unique properties of materials at the nanoscale—typically between 1 to 100 nanometers—to create innovative drug formulations that improve therapeutic efficacy, targeting, and patient compliance. Their work often involves designing nanoparticles, liposomes, nanoemulsions, and other nanocarriers that can enhance drug solubility, stability, and controlled release. By manipulating materials at such a minute scale, pharmaceutical nanotechnology experts enable drugs to cross biological barriers more effectively, reduce side effects by targeting specific tissues or cells, and develop novel treatment options for complex diseases such as cancer, neurological disorders, and infectious diseases.
The role of pharmaceutical nanotechnology experts extends beyond formulation development; they are also deeply involved in characterizing nanomaterials, assessing their safety and biocompatibility, and navigating regulatory pathways for novel nanomedicines. Their expertise requires interdisciplinary knowledge in pharmaceutics, materials science, molecular biology, and toxicology. As nanotechnology continues to revolutionize the pharmaceutical industry, these professionals play a crucial role in translating laboratory discoveries into clinically viable therapies. Their contributions not only pave the way for personalized medicine but also improve drug delivery efficiency, minimize toxicity, and ultimately enhance patient outcomes in modern healthcare.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia